Komori
KYORIN Pharmaceutical (4569) · InitiativeFirst stated

Acquisition of exclusive development and marketing rights for EB05 in Japan

First written in FY2027-H1. . Latest entry: FY2027-H1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Acquisition of exclusive development and marketing rights in Japan for EB05A theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Acquisition of exclusive development and marketing rights for EB05 in Japan | KYORIN Pharmaceutical Co.,Ltd. (4569) | Komori